U.S. Markets closed

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.4940+0.0140 (+2.92%)
At close: 04:00PM EST
0.4851 -0.01 (-1.80%)
After hours: 05:15PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5259
Bid0.5140 x 800
Ask0.4919 x 800
Day's Range0.5030 - 0.5486
52 Week Range0.4800 - 2.5900
Avg. Volume1,707,373
Market Cap112.202M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    Ampio (AMPE) Upgraded to Buy: Here's What You Should Know

    Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Zacks

    Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Ampio (AMPE)

    The heavy selling pressure might have exhausted for Ampio (AMPE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

  • Benzinga

    Why Ampio Pharmaceuticals Stock Is Trading Higher Today

    Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading higher Wednesday after the company announced top-line results from the AP-013 Phase III study of Ampion in patients suffering from severe osteoarthritis of the knee (OAK). Ampion demonstrated a statistically significant reduction in pain and improvement in function at 12 weeks in severe OAK patients. Ampio’s current cash runway is expected to provide sufficient near-term liquidity to support its existing business operations. Ampio said it